natgillin/translations-raw huggingface dataset:
Fibrater ATC- kode:
Fibrates ATC code:
C10A B04
C10A B04
LPL).
In man, gemfibrozil stimulates the peripheral lipolysis of triglyceride rich lipoproteins such as VLDL and cholymicrons (by stimulation of LPL).
Gemfibrozil hæmmer også syntesen af VLDL i leveren.
Gemfibrozil also inhibits synthesis of VLDL in the liver.
Gemfibrozil øger HDL2 og HDL3 subfraktionerne samt apolipoprotein A- I og A- II.
Gemfibrozil increases the HDL2 and HDL3 subfractions as well as apolipoprotein A-I and A-II.
Dyreforsøg antyder, at omsættelse og fjernelse af kolesterol fra leveren øges af gemfibrozil.
Animal studies suggest that the turnover and removal of cholesterol from the liver is increased by gemfibrozil.
I det kliniske studie, Helsinki Heart Study, der er et stort placebo- kontrolleret studie med 4081 mandlige patienter i alderen 40- 55 år med primær dyslipidæmi (hovedsagelig forhøjet ikke- HDL kolesterol + / - hypertriglyceridæmi), men ingen tidligere koronar hjertesygdom i anamnesen, viste at behandling med 600 mg gemfibrozil 2 gange dagligt signifikant kunne reducere total plasmatriglycerider, total og LD - lipoprotein kolesterol og gav en signifikant stigning i HD- lipoprotein kolesterol.
In the Helsinki Heart Study, which was a large placebo-controlled study with 4081 male subjects, 40 to 55 years of age, with primary dyslipidaemia (predominantly raised non-HDL cholesterol +/ - hypertriglyceridaemia), but no previous history of coronary heart disease, gemfibrozil 600 mg twice daily, produced a significant reduction in total plasma triglycerides, total and low density lipoprotein cholesterol and a significant increase in high density lipoprotein cholesterol.
Den kummulative hastighed af hjerte endepunkt (hjertedød og ikke- dødelig myokardieinfarkt) er i løbet af en 5 års opfølgningsperiode 27, 3/ 1000 i gemfibrozilgruppen (56 patienter) og 41, 4/ 1000 i placebogruppen (84 patienter) og viser en relativ risikoreduktion på 34% (95% konfidensinterval 8, 2- 52, 6, p < 0, 02) og en absolut risikoreduktion på 1, 4% i gemfibrozilgruppen sammenlignet med placebo.
The cumulative rate of cardiac end-points (cardiac death and non-fatal myocardial infarction) during a 5 year follow-up was 27.3/ 1000 in the gemfibrozil group (56 subjects) and 41.4/ 1000 in the placebo group (84 subjects) showing a relative risk reduction of 34.0% (95% confidence interval 8.2 to 52.6, p < 0.02) and an absolute risk reduction of 1.4% in the gemfibrozil group compared to placebo.
Der er en 37% reduktion i ikke- dødelig myokardieinfarkt og en 26% reduktion i hjertedød.
There was a 37% reduction in non-fatal myocardial infarction and a 26% reduction in cardiac deaths.
Imidlertidig er antallet af dødsfald af alle årsager ikke forskellig (44 i gemfibrozilgruppen og 43 i placebogruppen).
The number of deaths from all causes was, however, not different (44 in the gemfibrozil group and 43 in the placebo group).
Diabetespatienter og patienter med svær lipidfraktionsafvigelser viser en reduktion af CHD endepunkter på henholdsvis 68% og 71%.
Diabetes patients and patients with severe lipid fraction deviations showed a 68% and 71% reduction of CHD endpoints, respectively.
Absorption Gemfibrozil absorberes fuldstændigt i den gastrointestinale kanal efter oral anvendelse med en biotilgængelighed på næsten 100%.
Absorption Gemfibrozil is well absorbed from the gastro-intestinal tract after oral administration with a bioavailability close to 100%.
Da føde påvirker biotilgængeligheden en smule, bør gemfibrozil indtages 30 minutter før et måltid.
As the presence of food alters the bioavailability slightly gemfibrozil should be taken 30 minutes before a meal.
Maksimal plasmakoncentration opnås efter 1- 2 timer.
Peak plasma levels occur in one to two hours.
Ved indtagelse af 600 mg 2 gange dagligt opnås Cmax på 15- 25 mg/ ml.
After administration of 600 mg twice daily a Cmax in the range 15 to 25 mg/ ml is obtained.
Fordeling Fordelingsvolumen er 9- 13 l ved steady state.
Distribution Volume of distribution at steady state is 9-13 l.
Plasmaproteinbindingen af gemfibrozil og dets hovedmetabolit er mindst 97%.
The plasma protein binding of gemfibrozil and its main metabolite are at least 97%.
Biotransformation Gemfibrozil undergår oxidation af methylgruppen og danner efterhånden en hydroxymethyl - og en carboxylmetabolit. (hovedmetabolitten).
Biotransformation Gemfibrozil undergoes oxidation of a ring methyl group to form successively a hydroxymethyl and a carboxyl metabolite (the main metabolite).
20 timer.
This metabolite has a low activity compared to the mother compound gemfibrozil and an elimination half-life of approximately 20 hours.
Enzymerne, der er involveret i gemfibrozils metabolisme, er ikke kendt.
The enzymes involved in the metabolism of gemfibrozil are not known.
4. 3, 4. 4 og 4. 5).
The interaction profile of gemfibrozil is complex (see sections 4.3, 4.4 and 4.5).
In- vitro og in- vivo forsøg har vist, at gemfibrozil hæmmer CYP2C8, CYP2C9, CYP2C19, CYP1A2, UGTA1 og UGTA3.
In vitro and in vivo studies have shown that gemfibrozil inhibits CYP2C8, CYP2C9, CYP2C19, CYP1A2, UGTA1 and UGTA3.
Elimination Gemfibrozil udskilles hovedsagelig via metabolisme.
Elimination Gemfibrozil is eliminated mainly by metabolism.
Omtrent 70% af den humane dosis udskilles i urinen, hovedsagelig som konjugater af gemfibrozil og dets metabolitter.
Approximately 70% of the administered human dose is excreted in the urine, mainly as conjugates of gemfibrozil and its metabolites.
Mindre end 6% af dosis udskilles uomdannet i urin.
Less than 6% of the dose is excreteed unchanged in the urine.
6% af dosis genfindes i fæces.
Six percent of the dose is found in faeces.
Totalclearance af gemfibrozil er 100- 160 ml/ min, og eliminationshalveringstiden er 1, 3- 1, 5 timer.
The total clearance of gemfibrozil is in the range 100 to 160 ml/ min, and the elimination half-life is in the range 1.3 to 1.5 hours.
Ved terapeutiske doser ses liniær farmakokinetik.
The pharmacokinetics is linear within the therapeutic dose range.
Særlige patientgrupper Der er ikke udført farmakokinetikstudier hos patienter med nedsat leverfunktion.
Special patient groups No pharmacokinetic studies have been performed in patients with impaired hepatic function.
I et carcinogenicetetsstudie med mus i doser svarende til 0, 1 og 0, 7 gange den kliniske dosis (i forhold til AUC), ses ingen signifikante forskelle fra kontrolgruppen i hyppigheden af tumorer.
In a 2-year study of gemfibrozil, subcapsular bilateral cataracts occurred in 10%, and unilateral in 6.3%, of male rats treated at 10 times the human dose.
I et carcinogenicitetsstudie med rotter i doser svarende til 0, 2 og 1, 3 gange den kliniske dosis (i forhold til AUC), ses en signifikant øget hyppighed af benigne leverknuder og leverkarcinomer hos hanner, der fik høje doser, og hyppigheden af leverkarcinomer steg også hos hanner, der fik lave doser, men denne stigning var ikke signifikant.
In a rat carcinogenicity study at dosages corresponding to 0.2 and 1.3 times the clinical exposure (based on AUC), the incidence of benign liver nodules and liver carcinomas was significantly increased in high dose males, and the incidence of liver carcinomas increased also in the low dose males, but this increase was not statistically significant.
Gemfibrozil og andre fibrater inducerer levertumorer i små gnavere og er generelt relateret til den omfattende proliferation af peroxisomer i disse arter, og som konsekvens heraf af mindre klinisk betydning.
Liver tumours induced by gemfibrozil and other fibrates in small rodents are generally considered to be related to the extensive proliferation of peroxisomes in these species and, consequently, of minor clinical relevance.
Hos hanrotter inducerer gemfibrozil benign Leydig celletumorer.
In the male rat, gemfibrozil also induced benign Leydig cell tumors.
Den kliniske betydning af disse fund er minimal.
The clinical relevance of this finding is minimal.
I reproduktionstoksicitetsstudier med hanrotter fører administration af gemfibrozil ved doser omtrent 2 gange den humane dosis (i forhold til kropsoverflade) i 10 uger, til en nedgang i fertilitet.
In reproductive toxicity studies, administration of gemfibrozil at approximately 2 times the human dose (based on body surface area) to male rats for 10 weeks resulted in decreased fertility.
Fertiliteten genvindes efter en lægemiddelfri periode på 8 uger.
Fertility was restored after a drug-free period of 8 weeks.
Gemfibrozil er hverken teratogen i rotter eller kaniner.
Gemfibrozil was not teratogenic in either rats or rabbits.
Anvendelse af 1 og 3 gange den humane dosis (i forhold til kropsoverflade) af gemfibrozil til hunkaniner under organogenesen førte til en dosisrelateret nedgang i kuldstørrelse.
Administration of 1 and 3 times the human dose (based on body surface area) of gemfibrozil to female rabbits during organogenesis caused a dose-related decrease in litter size.
Anvendelse af 0, 6 og 2 gange den humane dosis (beregnet ud fra kropsoverflade) af gemfibrozil til hunrotter fra gestation dag 15 gennem afvænning, førte til dosisrelateret fald i fødselsvægt og undertrykkelse af vækst hos ungerne i ammeperioden.
Administration of 0.6 and 2 times the human dose (based on body surface area) of gemfibrozil to female rats from gestation Day 15 through weaning caused dose-related decreases in birth weight and suppression of pup growth during lactation.
Maternal toksicitet ses hos begge arter, og den kliniske betydning af nedgang i kuldstørrelse hos kaniner og rotteafkommets vægt er uvis.
Maternal toxicity was observed in both species and the clinical relevance of decreases in rabbit litter size and rat pup weight is uncertain.
[Implementeres nationalt]
[To be implemented nationally]
[Implementeres nationalt]
Not all pack sizes may be marketed [To be implemented nationally]
MARKEDSFØRINGSTILLADELSESNUMMER (NUMRE)
CHMP/ 1268/ 04 6.6 Instructions for use and handling
DATO FOR FØRSTE TILLADELSE/ FORNYELSE AF TILLADELSEN
DATE OF FIRST AUTHORIZATION/ RENEWAL OF AUTHORIZATION
LISTE OVER LÆGEMIDLERNES NAVNE, INDEHAVER AF MARKEDSFØRINGSTILLADELSE, STYRKER, LÆGEMIDDELFORM, INDGIVELSESVEJ, EMBALLAGE OG PAKNINGSSTØRRELSER I MEDLEMSSTATERNE
LIST OF THE INVENTED NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTE OF ADMINISTRATION, APPLICANTS/ MARKETING AUTHORISATION HOLDERS, PACKAGING AND PACKAGE SIZES IN THE MEMBER STATES
BEMÆRK VENLIGST AT ANSØGERE IKKE ER INKLUDERET I DENNE LISTE DA SÅDANNE OPLYSNINGER ER KONFIDENTIELLE
PLEASE NOTE THAT APPLICANTS ARE NOT INCLUDED IN THIS ANNEX FOR CONFIDENTIALITY REASONS
CPMP/ 1333/ 03
CPMP/ 1333/ 03
1/ 62
1/ 61
Medlems
Member
Indehaver af
Strength
Lægemidlets navn
Pharmaceutical
Lægemiddelfor
Packaging
Indgivelsesvej
Package
Emballage
State
Paknings
Name
stat
Form
markedsføringstilladelse m
administration
størrelse
size
Aesca chem. pharm.
Aesca chem. pharm.
Fabrik GmbH., Badner Straße 23, A- 2514 Traiskirchen, Østrig
Fabrik GmbH., Badner Straße 23, A-2514 Traiskirchen, Austria
Clarityn lösliche
Clarityn 10 mg - lösliche Tabletten
10 mg - 10 mg Tabletten
10 mg
Tabletbehol der
Tablet container
10, 30
10, 30
Fabrik GmbH.,
Fabrik GmbH., Badner Straße 23, A-2514 Traiskirchen, Austria
Clarityn
Clarityn 10 mg - Lyotabletten
10 mg - 10 mg
10 mg
Clarityn 10 mg Tabletten
Clarityn 10 mg Tabletten
Clarityn 5mg/ 5ml – Sirup
Clarityn 5mg/ 5ml – Sirup
5 mg/ 5 ml
5 mg/ 5 ml
Loratadin Aesca 10mg - Tabletten
Loratadin Aesca 10mg - Tabletten
Loratadin Aesca 5mg/ 5ml - Sirup
Loratadin Aesca 5mg/ 5ml - Sirup
Loratyn 10 mg - Brausetabletten
Loratyn 10 mg - Brausetablette n
Brusetablet
Effervescent tablet
2/ 62
2/ 61
Loratyn
Loratyn 10 mg - Lyotabletten
Arcana Arzneimittel GmbH., Zimbagasse 5, A- 1147 Wien Østrig
Arcana Arzneimittel GmbH., Zimbagasse 5, A-1147 Wien Austria
Loratadin arcana 10 mg - Filmtabletten
Loratadin arcana 10 mg- Filmtabletten
5, 7, 10, 14, 15, 20, 21, 30, 50, 100
5, 7, 10, 14, 15, 20, 21, 30, 50, 100
Lannacher Heilmittelwerke GmbH, Schloßplatz 1, A- 8502 Lannach Østrig
Lannacher Heilmittelwerke GmbH, Schloßplatz 1, A-8502 Lannach Austria
Lorat 10 mg - Tabletten
Lorat 10 mg - Tabletten
7, 10, 20, 30, 50, 100
7, 10, 20, 30, 50, 100
Liconsa S. A.
Liconsa S. A.
Gran Via Carlos III, 98 ES- 08028 Barcelona Spanien
Gran Via Carlos III, 98 ES-08028 Barcelona Spain
Chemotadin 10 mg - Tabletten
Chemotadin 10 mg - Tabletten
Lindopharm GmbH., Neustraße 82, D- 40721 Hilden Tyskland
Lindopharm GmbH., Neustraße 82, D-40721 Hilden Germany
Loratadin Lindopharm 10 mg Tabletten
Loratadin Lindopharm 10 mg Tabletten
Ratiopharm Arzneimittel Vertriebs - GmbH, Alöbert Schweitzer Gasse 3, A- 1147 Wien Østrig
Ratiopharm Arzneimittel Vertriebs- GmbH, Alöbert Schweitzer Gasse 3, A-1147 Wien Austria
Loratadin ratiopharm 10 mg - Tabletten
Loratadin ratiopharm 10 mg - Tabletten
7, 20, 50, 100
7, 20, 50, 100
Sandoz GmbH., A- 6250 Kundl/ Tirol Østrig
Sandoz GmbH., A-6250 Kundl/ Tirol Austria
Lictyn 10 mg - Tabletten
Lictyn 10 mg - Tabletten
7, 10, 14, 20, 21, 30, 50, 60, 100, 250
7, 10, 14, 20, 21, 30, 50, 60, 100, 250
3/ 62
3/ 61
Stada Arzneimittel GmbH, Heiligenstädterstraße 52/ 8, A- 1190 Wien, Østrig
Stada Arzneimittel GmbH, Heiligenstädterstraße 52/ 8, A-1190 Wien, Austria
Loratadine “ Stada ” 10 mg Tabletten
Loratadine “ Stada” 10 mg Tabletten
1, 5, 7, 10, 14, 15, 20, 21, 30, 50, 60, 90, 100, 250
1, 5, 7, 10, 14, 15, 20, 21, 30, 50, 60, 90, 100, 250
Loratadine “ Stada ” 1 mg/ ml Sirup
Loratadine “ Stada” 1 mg/ ml Sirup
5mg/ 5 ml
5mg/ 5 ml
50, 60, 100, 120, 150ml
50, 60, 100, 120, 150ml
Omega Pharma N. V.
Omega Pharma N. V.
Venecoweg 26 B- 9810 Nazareth Belgien
Venecoweg 26 B-9810 Nazareth Belgium
Sanelor
Sanelor
Laboratoires Irex Avenue galilee F- 92350 Le Plessis- Robinson, Cedex Frankrig
Laboratoires Irex Avenue galilee F-92350 Le Plessis-Robinson, Cedex France
Loratadine irex
Loratadine irex
7, 20, 30, 50, 100
7, 20, 30, 50, 100
Merck NV Brusselsesteenweg 288 B- 3090 Overijse Belgien
Merck NV Brusselsesteenweg 288 B-3090 Overijse Belgium
Merck- loratadine
Merck- loratadine
4/ 62
4/ 61
Paknings
administration
stat
size
markedsføringstilladelse m
Rue de Stalle 73 B-1180 Brussels Belgium
størrelse
7, 21 1, 2, 5, 7, 10, 14, 20, 21, 28, 30, 42, 50, 56, 100, 500 - for export
Rue de Stalle 73 B- 1180 Brussels Belgien
Rue de Stalle 73 B-1180 Brussels Belgium
Claritine
Claritine
10, 21 10, 14, 15, 21, 30 - for export
10, 21 10, 14, 15, 21, 30 - for export
100 ml 50, 60, 100, 120, 150 ml – for export
100 ml 50, 60, 100, 120, 150 ml – for export
Claritine Reditabs
Claritine Reditabs
Smeltetablet
Oral Lyophilisate
10, 20, 30
10, 20, 30
1A Farma Herstedøstervej 27- 29 DK- 2620 Albertslund.
1A Farma Herstedøstervej 27-29 DK-2620 Albertslund.
Loratadin 1A Pharma
Loratadin 1A Pharma
10, 30, 100
10, 30, 100
A/ S GEA Farmaceutiske Fabrik, Holger Danskes Vej 89, DK- 2000 Frederiksberg, Danmark
A/ S GEA Farmaceutiske Fabrik, Holger Danskes Vej 89, DK-2000 Frederiksberg, Denmark
Geklimon
Geklimon
Ct- Arzneimittel GmbH Lengeder Str.
Ct-Arzneimittel GmbH
Loratadin ct
Loratadin ct
10 mg
Not
5/ 62
5/ 61
markedsføringstilladelse m
42a D-13407 Berlin Germany
størrelse
5, 10, 30, 100
HEXAL AG Industriestr.
HEXAL AG Industriestr.
25 D- 83607 Holzkirchen Tyskland
25 D-83607 Holzkirchen Germany
Medallerg
Medallerg
Ikke på markedet i øjeblikket
Not marketed at the moment
Lichtenstein Pharmazeutica GmbH Industriestrasse 10 D- 56218 Mulheim- Karlich Tyskland
Lichtenstein Pharmazeutica GmbH Industriestrasse 10 D-56218 Mulheim-Karlich Germany
Loratadin Lichtenstein
Loratadin Lichtenstein
Linconsa SA.
Linconsa SA.
Gran Via Carlos III 98, 7 Planta ES- 08028 Barcelona Spanien
Gran Via Carlos III 98, 7 Planta ES-08028 Barcelona Spain
Chemolorat
Chemolorat
Chemotadin
Chemotadin
Licatidin
Licatidin
Ikke på markedet I øjeblikket
Not marketed at the moment
Loralic
Loralic
Lorat
Lorat
Ikke på markedet I øjeblikket
Not
6/ 62
6/ 61
markedsføringstilladelse m
Gran Via Carlos III 98, 7 Planta ES-08028 Barcelona Spain
størrelse
marketed at the moment
Loratadin “ Liconsa ”
Loratadin "Liconsa"
Tifitadin
Tifitadin
Medis Danmark A/ S Havelse Mølle 14 DK- 3600 Frederikssund Danmark
Medis Danmark A/ S Havelse Mølle 14 DK-3600 Frederikssund Denmark
Solamed
Solamed
Delor
Delor
Medis Danmark A/ S, Havelse Mølle 14, DK- 3600 Frederikssund Danmark
Medis Danmark A/ S, Havelse Mølle 14, DK-3600 Frederikssund Denmark
Loratadin Medis
Loratadin Medis
Ongoing.
Ongoing.
Packsizes not decided
Packsizes not decided
Medis Danmark A/ S, Havelse Mølle 14 DK- 3600 Frederikssund Danmark
Medis Danmark A/ S, Havelse Mølle 14 DK-3600 Frederikssund Denmark
Loratabs
Loratabs
Loarev
Loarev
7/ 62
7/ 61
Lorafluid
Lorafluid
Loramix
Loramix
Lorfuse
Lorfuse
Lorasol
Lorasol
Deloradin
Deloradin
Alerzid
Alerzid
NM Pharma A/ S.
NM Pharma A/ S.
Lautrupvang 8, DK- 2750 BallerupDanmark
Lautrupvang 8, DK-2750 Ballerup Denmark
Loratadin ” NM ”
Loratadin "NM"
8/ 62
8/ 61
Lægemidlets navn
Marketing Authorisation Holder
Styrke
Invented
Lægemiddelfor
Strength
Emballage
Route of
Paknings
Packaging
stat
Package
størrelse
State
DK
Name
1 mg/ ml
Form
Oral anvendelse
administration
Flaske
size
Ratiopharm GmbH, Graf- Acro- Strasse 3, D- 89079 Ulm, Tyskland
Ratiopharm GmbH, Graf-Acro-Strasse 3, D-89079 Ulm, Germany
Loratadin Ratiopharm
Loratadin Ratiopharm
Loratadin Biochemie
Loratadin Biochemie
Schering Plough Europé Rue de Stalle 73 B- 1180 Brussels Belgien
Schering Plough Europe Rue de Stalle 73 B-1180 Brussels Belgium
Clarityn
Clarityn
5, 10, 30, 100
5, 10, 30, 100
1 x 100 ml
1 x 100 ml
Schering Plough Europe Rue de Stalle 73 B- 1180 Brussels Belgien
Schering Plough Europe Rue de Stalle 73 B-1180 Brussels Belgium
9/ 62
9/ 61
Schering- Plough A/ S Hvedemarken 12 DK- 3520 Farum Danmark
STADA Arzneimittel AG Stadastrasse 2-18 D-61118 Bad Vilbel Germany
Versal
Loratadin STADA
Ikke på markedet i øjeblikket
10, 30, 50, 100
Allergostad
Loradis
Ikke på markedet i øjeblikket
Not marked at the moment
Loratadin STADA
Lorapharm
10, 30, 50, 100
Not marked at the moment
STADA Arzneimittel AG Stadastrasse 2- 18 D- 61118 Bad Vilbel Tyskland
Sterwin Medicines Ltd 1 Onslow Street, Guildford Surrey GU1 4YS, United Kingdom
Loradis
Lorafile
STADA Arzneimittel AG Stadastrasse 2- 18 D- 61118 Bad Vilbel Tyskland
Calwerstrasse 7 D-71034 Böblingen, Germany
Lorapharm
LORATAGA MMA
DK
FI
Sterwin Medicines Ltd 1 Onslow Street, Guildford Surrey GU1 4YS, Det Forenede Kongerige
A/ S Gea Farmaceutisk Fabrik, Holger Danskes Vej 89, DK-2000 Frederiksberg, Denmark
Lorafile
Geklimon
Ikke på markedet i øjeblikket
7, 10, 20, 21, 30, 100
Calwerstrasse 7 D- 71034 Böblingen, Tyskland
DuraScan Medical Products AS, Svendborgvej 243, DK-5260 Odense S, Denmark
LORATAGAMM A
Loratadin Durascan
Ikke på markedet i øjeblikket
5, 7, 10, 14, 20, 30, 40, 100, 105
10/ 62
10/ 61
Paknings
Route of
Geklimon
Package
Tablet
State
10 mg
Name
Tablet
Form
Blister
size
Generics (UK) Limited, Station Close, Potters Bar, Herts EN6 1TL, Det Forenede Kongerige
Generics (UK) Limited, Station Close, Potters Bar, Herts EN6 1TL, United Kingdom
Loratadin Generics
Loratadin Generics
Laboratoires SMB S. A., Rue de la Pastorale 26- 28, B- 1080 Brussels, Belgien
Laboratoires SMB S. A., Rue de la Pastorale 26-28, B-1080 Brussels, Belgium
Histadin
Histadin
Ratiopharm GmbH, Graf- Arco- Strasse 3, D- 89079 Ulm, Tyskland
Ratiopharm GmbH, Graf-Arco-Strasse 3, D-89079 Ulm, Germany
Loratadin - ratiopharm
Loratadin- ratiopharm
2, 7, 10, 20, 30, 50, 100
2, 7, 10, 20, 30, 50, 100
Sandoz GmbH, Biochemiestrasse 10, A- 6250 Kundl, Østrig
Sandoz GmbH, Biochemiestrasse 10, A-6250 Kundl, Austria
Blister og Tabletbehol der
Blister and tablet container
7, 10, 14, 20, 21, 30, 50, 60, 100, 100x1, 250
7, 10, 14, 20, 21, 30, 50, 60, 100, 100x1,25 0
Schering- Plough Europe, 73, Rue De Stalle, B- 1180 Brussels, Belgien
Schering-Plough Europe, 73, Rue De Stalle, B-1180 Brussels, Belgium
Clarityn- S
Clarityn-S
8, 10, 30, 100,
8, 10, 30, 100,
STADA Arzneimittel AG, Stadastrasse 2- 18, D- 61118 Bad Vilbel, Tyskland
STADA Arzneimittel AG, Stadastrasse 2-18, D-61118 Bad Vilbel, Germany
Loratadin Stada
Loratadin Stada
50, 60, 100, 120, 150 ml
50, 60, 100, 120, 150 ml
Verman Oy Ab, Vanhankyläntie 44 B, FIN- 04401 Järvenpää, Finland
Verman Oy Ab, Vanhankyläntie 44 B, FIN-04401 Järvenpää, Finland
Tuulix
Tuulix
1, 10, 30, 100
1, 10, 30, 100
60, 100, 200 ml
60, 100, 200 ml
ENDWELL Elm House Ashbourne Industrial Estate Ashbourne - County Meath Irland
ENDWELL Elm House Ashbourne Industrial Estate Ashbourne - County Meath Ireland
LORATADINE ENDWELL
LORATADIN E ENDWELL
15, 28, 30, 100
15, 28, 30, 100
Generics 28 Station Close Potters Bar EN6 1TL Hertfordshire, Det Forenede Kongerige
Generics 28 Station Close Potters Bar EN6 1TL Hertfordshire, United Kingdom
LORATADINE
LORATADIN E
5, 7, 10, 14, 15
5, 7, 10, 14, 15
LORATADINE MADAUS
MADAUS
Tablets
Tablets
Blister (PVC/ Alu)
Blister
15, 28, 30
15, 28, 30
Schering Plough 92, rue Baudin F- 92307 Levallois Perret Cedex, Frankrig
Schering Plough 92, rue Baudin F-92307 Levallois Perret Cedex, France
CLARITYNE
CLARITYNE
0. 1 g/ 100ml
0.1 g/ 100ml
Glass (brun)
Glass (brown)
60, 120 ml
60, 120 ml
10, 15, 20
10, 15, 20
Blister (Alu/ Alu)
Blister (Alu/ Alu)
7, 10, 14, 15, 20, 21, 30
7, 10, 14, 15, 20, 21, 30
LORATADINE SCHERING PLOUGH
LORATADIN E SCHERING PLOUGH
0. 10%
0.10%
60, 125ml
60, 125ml
VIARO
VIARO
5, 7, 10, 15
5, 7, 10, 15
GE
GE
1 A Pharma GmbH Keltenring 1+3 D- 82041 Oberaching Tyskland
1 A Pharma GmbH Keltenring 1+3 D-82041 Oberaching Germany
Loratad 10 mg
Loratad
1 A Pharma GmbH Keltenring 1 + 3 D- 82041 Oberhaching Tyskland
1 A Pharma GmbH Keltenring 1 + 3 D-82041 Oberhaching Germany
Loratad 10
Loratad 10
7, 10, 14, 20, 21, 30, 50, 100
7, 10, 14, 20, 21, 30, 50, 100
Loratadin- 1A Pharma
Loratadin-1A Pharma
20, 30, 50, 100
20, 30, 50, 100
Acis Arzneimittel Vertrieb AG Bajuwarenring 14 D- 82041 Oberhachling Tyskland
Acis Arzneimittel Vertrieb AG Bajuwarenring 14 D-82041 Oberhachling Germany
Loratadin Acis 10 mg
Loratadin Acis 10 mg
Blister (PVC/ PVD C/ Alu)
Blister (PVC/ PVD C/ Alu)
Alfred E. Tiefenbacher GmbH & Co.
Alfred E. Tiefenbacher GmbH & Co.
Van- der- Schmissen- Str 1 D- 22767 Hamburg Tyskland
Van-der-Schmissen-Str 1 D-22767 Hamburg Germany
Chemotadin 10 mg Tabletten
Chemotadin 10 mg Tabletten
Alfred E. Tiefenbacher GmbH & Co.
Alfred E. Tiefenbacher GmbH &
Lorat 10 mg Tabletten
Lorat
7, 10, 20, 30, 50, 100
7, 10, 20,
GE
Co.
Aliud Pharma GmbH & Co KG Gottlieb- Daimler Str 19 D- 89150 Laichingen Tyskland
Van-der-Schmissen-Str 1 D-22767 Hamburg Germany
Loratadin AL 10 mg Tabletten
Tabletten
Blister (PVC/ Alu)
(PVC/ Alu)
7, 20, 50, 100
30, 50, 100
Aliud Pharma GmbH & Co KG Gottlieb- Daimler Str 19 D- 89150 Laichingen Tyskland
Aliud Pharma GmbH & Co KG Gottlieb-Daimler Str 19 D-89150 Laichingen Germany
10 mg
Loratadin AL 10 mg Tabletten
10, 20, 50, 100
7, 20, 50, 100
15/ 62
14/ 61
7- 13 D- 01097 Dresden Tyskland
Aliud Pharma GmbH & Co KG Gottlieb-Daimler Str 19 D-89150 Laichingen Germany
Loralerg
Loratadin AL 1 1 mg/ ml saft
10 mg
1 mg/ 1ml
Tablet
Syrup
Blister (PVC/ Alu)
Bottle (PE)
7, 20, 50, 100, 500
50, 60, 100, 120, 150 ml
Basics GmbH Hemmelrather Weg 201 D- 51377 Leverkusen Tyskland
1 D-40764 Langenfeld Germany
! LORA BASICS
LORA- PUREN
7, 20, 50, 100
7, 10, 20, 50, 100, 500
BC Biochemie Carl- Zeiss- Ring 3 D- 85737 Ismaning Tyskland
Altana Consumer Health GmbH Bargkoppelweg 66 D-22145 Hamburg Germany
TRILOR 10 mg Tabletten
Enatin
Blister (PVC/ AL, P VC/ AL/ PV DC, PVC/ P E, PVDC/ A L)
Blister (PVC/ Alu)
7, 10, 20, 50, 100
10, 20, 50, 100
Betapharm Arzneimittel GmbH Kobelweg 95 D- 86156 Augsburg Tyskland
7-13 D-01097 Dresden Germany
Betalora 10
Loralerg
7, 10, 20, 30, 50, 100
7, 20, 50, 100, 500
Betapharm Arzneimittel GmbH Kobelweg 95 D- 86156 Augsburg Tyskland
Basics GmbH Hemmelrather Weg 201 D-51377 Leverkusen Germany
Lobeta gegen Allergien
! LORA BASICS
42a D- 13407 Berlin Tyskland
BC Biochemie Carl-Zeiss-Ring 3 D-85737 Ismaning Germany
Loratadin von ct
TRILOR 10 mg Tabletten
Blister (PVC/ Alu)
Blister (PVC/ AL, PVC/ AL/ P VDC, PVC/ PE, PVDC/ AL)
7, 20, 50, 100
7, 10, 20, 50, 100
42a D- 13407 Berlin Tyskland
Betapharm Arzneimittel GmbH Kobelweg 95 D-86156 Augsburg Germany
Loratadin von ct
Betalora 10
Blister (PVC/ PVD C/ Alu)
Blister (PVC/ Alu)
7, 20, 50, 100
7, 10, 20, 30, 50, 100
16/ 62
15/ 61
6 D- 82031 Gruenwald Tyskland
Betapharm Arzneimittel GmbH Kobelweg 95 D-86156 Augsburg Germany
Loraderm
Lobeta gegen Allergien